Mersana Therapeutics, Inc. (MRSN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Mersana Therapeutics, Inc. (MRSN)
Go deeper and ask any question about MRSN
Company Performance
Current Price
as of Sep 13, 2024$2.11
P/E Ratio
N/A
Market Cap
$258.84M
Description
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerMRSN
- Price$2.11+19.21%
Trading Information
- Market Cap$258.84M
- Float73.65%
- Average Daily Volume (1m)962,655
- Average Daily Volume (3m)1,257,816
- EPS-$0.86
Company
- Revenue$29.94M
- Rev Growth (1yr)-78.48%
- Net Income-$24.27M
- Gross Margin82.42%
- EBITDA Margin-1,092.54%
- EBITDA-$25.05M
- EV$115.67M
- EV/Revenue3.86
- P/EN/A
- P/S8.63
Documents
SEC Filings
Earnings Calls